

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 December 2022 (22.12.2022)



(10) International Publication Number
WO 2022/265993 A1

(51) International Patent Classification:

C07D 307/81 (2006.01) C07D 497/10 (2006.01)
C07D 403/12 (2006.01) A61K 31/343 (2006.01)
C07D 405/12 (2006.01) A61K 31/443 (2006.01)
C07D 409/12 (2006.01) A61K 31/506 (2006.01)
C07D 413/12 (2006.01) A61P 35/00 (2006.01)
C07D 413/14 (2006.01)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/033255

(22) International Filing Date:

13 June 2022 (13.06.2022)

(25) Filing Language:

English

Published:

— with international search report (Art. 21(3))

(26) Publication Language:

English

(30) Priority Data:

63/210,370	14 June 2021 (14.06.2021)	US
63/228,351	02 August 2021 (02.08.2021)	US
63/288,909	13 December 2021 (13.12.2021)	US
63/316,017	03 March 2022 (03.03.2022)	US
63/319,236	11 March 2022 (11.03.2022)	US
63/348,261	02 June 2022 (02.06.2022)	US


(71) Applicant: **SCORPION THERAPEUTICS, INC.**
[US/US]; One Winthrop Square, Suite 400, Boston, Massachusetts 02110 (US).

(72) Inventors: **ST. JEAN, JR., David**; 25 Hunters Ln., Natick, Massachusetts 01760 (US). **CUMMINGS, Maxwell David**; One Winthrop Square, Suite 400, Boston, Massachusetts 02110 (US).

(74) Agent: **BATES, Caleb A.** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER



(57) Abstract: This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Ka activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.



WO 2022/265993 A1